Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Inclusion Criteria: * Patients must weigh ≥10 kilograms at the time of study enrollment. * Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria: Low Risk Cohort (LR cohort): * Any patient with FIRST RELAPSE \> ONE YEAR from initial diagnosis of de novo ALK+ ALCL, * Common histology, * CD3 negative, AND * No prior exposure to vinblastine (VBL). High-Risk Cohort (HR cohort): * Any patient with RELAPSED OR PROGRESSIVE DISEASE less than ONE YEAR from initial diagnosis of de novo ALK+ ALCL, * Small cell/histiocytic histology, * CD3 positive (homogeneous staining of CD3 positive T-cells) * Patients must have adequate organ function. * Patients must have performance status 60 or above. Exclusion Criteria: * ALK-NEGATIVE anaplastic large cell lymphoma. * Patients with active leptomeningeal disease (lymphoma cells in CSF). * Previous treatment with vinblastine (only in patients in the LR cohort). * Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarche. * Lactating females unless they have agreed not to breastfeed their infants. * Patients with Down syndrome. * Any patient with uncontrolled infection prior to study entry. * Any patient known to have primary or acquired immunodeficiency and/or prior solid organ transplant.